REVIEW

Menopause hormone therapy: latest developments and clinical practice

Tomas Fait MD, PhD
Department of Obstetrics and Gynecology, Faculty Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic

Abstract
Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.

Keywords: atrophic vaginitis, bazedoxifene, climacteric syndrome, menopause hormone therapy, phytoestrogens, tibolone.

Citation
Fait T. Menopause hormone therapy: latest developments and clinical practice. Drugs in Context 2019; 8: 212551. DOI: 10.7573/dic.212551

Introduction
The extensive climacteric symptomatology falls into somatic (vegetative) symptoms (vasomotor disorders, psychic disorders), organic symptoms (skin changes, urogenital changes, weight changes), and metabolic symptoms (lipid spectrum changes, atherosclerosis, osteoporosis).

Pharmacotherapy can be divided into hormonal and nonhormonal therapy. Menopause hormone therapy (MHT), or hormone replacement therapy (HRT), consists of a group of preparations with sex hormones administered in cases of low level of estrogen. Estrogen-only therapy is labeled as estrogen replacement therapy (ET, ERT). For combination of estrogens and progestogens, the term is estrogen–progestogen therapy (EPT). It is advisable to distinguish between them because of significant differences in their benefit–risk ratio.

Therapeutic administration of estrogens results in removing almost all climacteric symptoms. Their administration is an effective strategy for the long-term prevention of estrogen deficiency as well as some other diseases where a direct connection is not obvious.

The hormone therapy of choice for women in early menopausal transition is gestagen substitution, levonorgestrel intrauterine system (LNG-IUS), or low-dose monophasic contraception. In late menopausal transition, there should be an initial switch to gestagen-dominated combined sequential EPT. Start with low doses and, if not effective, increase the dose. In an effort to maintain the cycle, the patient’s wishes, the duration of administration of the replacement therapy, and the patient’s age should be considered. Sometimes, the age of 52 is said to be a threshold for administering sequential EPT. Later, in postmenopausal cases, a switch to combined continuous EPT is recommended. This is also a therapy of choice in postmenopausal women who have not used MHT so far (Table 1).

Menopause hormone therapy

Estrogens can be administered orally, transdermally, percutaneously, intramuscularly, intranasally, subcutaneously, or locally (vaginally) with doses and timing tailored to each patient.

The transdermal administration is preferred in case of oral treatment intolerance, alteration of liver function, hypertriglyceridermia, diabetes mellitus, and in case of a risk of thromboembolic disease. This administration route bypasses the first-pass effect seen with the oral route of administration and the resulting load of the liver cell, provides better bioavailability, and facilitates a long-term balance of estrogen levels and the physiological ratio of the levels of estradiol and estrone.

The newest application method is the metered-dose transdermal spray (EMDTS). In one recent study, the serum levels of estradiol, estrone, and estrone sulfate increased
with the number of EMDTS 1.53 mg doses in symptomatic menopausal women.3 Maximum levels were 36 pg/mL estradiol and 50 pg/mL estrone after one puff, and 54 pg/mL and 71 pg/mL after three puffs. The maximum estradiol concentration was achieved 18–20 hours after application. A stable level was reached on the 7th–8th day of application. Transdermal estrogen spray combines the advantages of safety of transdermal application with the possibility of precise dosing.3

ET is for women without a uterus. For women with intact uterus, estrogen–progestogen blends are administered, and their application regimen consists of continual administration or cyclic administration for 21 days with a 7-day pause. Standard and low doses of estrogens have mitogenic activity for endometrium cells; therefore, they must be administered in combination with progestins to women with an intact uterus. Progestins administered continuously or sequentially for 10–14 days in the second half of the cycle cause endometrium growth and thus also pseudomenstrual bleeding. The progestin used affects clinical and metabolic effects of the preparation. In practice, micronized progesterone and dydrogesterone appear to have the most favorable safety profile from all progestogens. IUS-LNG has a local effect on the endometrium with minimal systemic effects.4

Benefits of menopause hormone therapy

Vasomotor symptoms

Vasomotor symptoms (VMS) in menopause are associated with sleeping disorders, concentration disorders, and lowered quality of life and overall health condition (cardiovascular risk, cognitive functions, bone loss). They last on average for 7.4 years. Estrogens reduce the frequency of symptoms by 75% and their intensity by 87%. Low doses (conjugated equine estrogen [CEE] 0.3 mg, estradiol 0.5 mg, estradiol patch 0.025 mg) need 6–8 weeks to reach their maximum effect.5 Gestagen therapy (medroxyprogesterone acetate 10 mg per day, megestrol acetate 20 mg per day, micronized progesterone 300 mg) is effective, but it does not have long-term safety data. After discontinuing treatment, the problems return in about 50% of women. It has not been proved whether it is better to quit ‘cold turkey’ or step by step.6

Sleeping disorders

MHT improves chronic insomnia in menopausal women. Some progestogens (especially oral micronized progesterone) have a slight sedative effect probably due to their agonistic action on gamma-aminobutyric acid (GABA) receptors.7

Sexuality

The positive effect of estrogens on sexuality is caused by resolving vulvovaginal atrophy (VVA) and reducing VMS. Other mechanisms have not been proved. Transdermal estrogens are preferred to oral estrogens in women with lowered libido because they do not increase the level of sex hormone-binding globulin (SHBG) and thus do not reduce bioavailability of testosterone.8 Continuous testosterone therapy has benefits for women diagnosed with hypoactive sexual desire disorders.9

Premature ovarian insufficiency

Premature ovarian insufficiency (POI), or premature ovarian failure or premature menopause, is defined as a primary hypogonadism before the age of 40 years. Premature onset of estrogen deficiency is associated with a risk of persistent VMS, bone loss, VVA, mood swings, ischemic cardiac disease, dementia, cerebrovascular accidents, Parkinsonism, eye disorders, and increased overall mortality. POI management includes, besides suitable MHT, calcium supplements, vitamin D, and exercise. Hormonal contraception without a hormone-free interval is also suitable.10 POI is a mandatory indication for hormone therapy.

Quality of life

MHT increases quality of life by eliminating VMS symptoms.11 Estrogens modify the course of inflammation and regeneration...
of the epithelium. They improve the quality of skin. MHT increases the risk of dry eye syndrome but reduces the risk of cataract and glaucoma.

**Musculoskeletal system**

A standard dose of estrogen prevents bone loss by inhibition of osteoclast activity and reducing bone turnover, and reduces the number of osteoporosis fractures in all locations – even in women without osteoporosis. However, MHT is not first-line therapy position for osteoporosis, but is best for prevention of osteoporosis. Studies about the effect on joints have inconsistent results but the positive effect prevails. The effect of MHT on frailty syndrome and sarcopenia is positive especially in combination with exercise.

**Diabetes mellitus**

MHT users have a significantly lower risk of the onset of type 2 diabetes mellitus. Its protective effect disappears when discontinued. Estrogens may help to prevent fat accumulation by stimulating estrogen receptor alpha.

**Depression and memory**

MHT improves mood and has a positive effect on menopause-associated depression. Cognitive functions are improved by MHT only in case of an early start (critical window hypothesis, healthy cell bias hypothesis). On the contrary, at the age over 65, it increases the risk of dementia. The same dependence applies to Alzheimer’s disease.

**Cardiovascular diseases**

The positive effect of MHT on ischemic cardiac disease prevails in healthy women within 10 years of their menopause or, more precisely, until the age of 60 years the number of cerebrovascular accidents does not increase. According to the Cochrane database, the risk ratio (RR) of ischemic cardiac disease is 0.52 and RR for overall mortality is 0.7 when MHT is started within 10 years from the menopause.

**Risks of menopause hormone therapy**

As with every therapeutic agent, MHT brings certain risks and undesirable side effects that should be taken into account.

Mastodynia, fluid retention, nausea, lower extremities cramps, and headache may occur during usage of estrogens. Depression, anxiety, flatulence, and increased appetite are associated with the gestagen components. When using MHT, unwanted bleeding caused by a decrease in hormone levels, may be detected.

Relative contraindications of MHT such as hypertension, ischemic cardiac disease, diabetes mellitus, migraine, benign breast disease, uterus myomatosus, and endometriosis have nowadays been abandoned as unjustified. There are only several instances where MHT is contraindicated (Box 1).

Long-term use of MHT (more than 10 years) increases the risk of breast cancer by 10–30%. Estrogens do not induce breast cancer as oncogenes but may become a promoter of its growth. In 1997, the Collaborative Group on Hormonal Factors in Breast Cancer published a reanalysis of 51 epidemiologic studies (52,705 women with carcinoma, 108,411 healthy women) and found a relative risk (RR) when used for less than 5 years of 1.023 per year of use, and an RR of 1.35 when used for more than 5 years. At 5 years after discontinuing MHT, the RR was 1.0 independent on the length of use. The influence of MHT decreases with increasing body mass index (BMI).

**Box 1. Contraindications of MHT.**

- Breast carcinoma – current, in personal anamnesis, suspected
  - invasive breast carcinoma, premalignant changes of breast (atypical ductal hyperplasia, lobular neoplasia) and a ductal carcinoma *in situ* (intraductal carcinoma)
- Estrogen-dependent malignant carcinoma – known or suspected
  - e.g. unfounded bleeding from genitals as a sign of endometrial carcinoma
- Untreated estrogen-dependent carcinomas
  - endometrial carcinoma, breast carcinoma, endometrial stromal sarcoma
- Active hepatopathy
- Anamnestic or current idiopathic thromboembolic disease
  - pulmonary embolism, phlebothrombosis
- Active or recent arterial thromboembolism
  - e.g. coronary thrombosis, angina pectoris
- Known intolerance to a certain constituent of the preparation.

MHT, menopause hormone therapy.
Beral and colleagues summarized the results of the following studies: HERS, WHI, WEST, and EVTET. These were placebo-controlled, prospective studies with more than 20,000 women observed for 4–9 years. In summary, they stated that MHT significantly increases the risk of thromboembolic disease (TEN) with an RR of 2.16.

The ESTHER study comprised 155 TEN cases and 381 controls. The results showed, not only a significant RR of thromboembolic disease for users of oral estrogen replacement therapy (RR 3.5 [Cl: 1.8–6.8]) compared with women without treatment, but also with women undergoing transdermal treatment (RR 4 [Cl: 1.9–8.3]). There is an RR of 2.3–9.5 that endometrial carcinoma may arise in women with intact uterus when using unopposed estrogens. Adding progestin reduces the risk to a value lower than the value in nonusers. That has been proved even by the EPT arm of the WHI study (RR 0.81 [0.46–1.36]).

Tibolone

Tibolone is a progestogen with selective tissue estrogenic activity. It exhibits weak estrogenic, progestogenic, and androgenic activity. It suppresses vasomotor problems and improves mood and libido at the recommended dose of 2.5 mg/day. It improves vaginal atrophy but it does not affect the endometrium. It has a protective effect on bone mass, even in a dose of 1.25 mg/day. It reduces proliferation of breast epithelial cells, does not increase mammographic density, and reduces cyst diameter of fibrocystic mastopathy. Tibolone is a therapy of choice for women with a history of endometriosis and unwanted side effects with conventional MHT (Box 2). However, prolonged use of tibolone in older women has been associated with an increased risk of stroke. There is also evidence that tibolone could slightly increase the risk of recurrence in breast cancer patients.

Estetrol

In the 1960s, estetrol $E_4$ joined the hitherto known natural estrogens – estrone $E_1$, estradiol $E_2$, and estriol $E_3$. It is a steroid with an estrogen structure and four hydroxyl groups: $\text{estra-1, 3, 5(10)-tien-3, 15\alpha,16\alpha,17\beta}$-tetrol. It can be also called $15\alpha$-hydroxyestriol. It is produced exclusively by cell microsomes of fetal liver.

Estetrol has a very good oral bioavailability: 70% in comparison with subcutaneous application. It binds to estrogen receptor (ER) alpha 4–5 times stronger than to ER beta. Unlike the other estrogens, it does not induce production of SHBG and does not bind to it. Initial studies showed efficacy at tested doses of 2 and 10 mg $E_4$ per day.

The potential of $E_4$ when used as hormone replacement in women after breast cancer surgery, in women treated by aromatase inhibitors or tamoxifen, has been indicated by initial observation within a clinical study.

---

**Box 2. Guidelines on tibolone administration: when to prefer tibolone to MHT.**

| Postmenopausal women with acute climacteric syndrome |
|------------------------------------------------------|
| • Lower sexual appetite or sexual dysfunction         |
| • Mood swings                                        |
| • Accelerated bone loss (osteoporosis prevention during the early postmenopausal period) |
| • Anamnesis of premenopausal mastalgia and breast tension |
| • High breast density                                |
| • Myomas                                            |
| • Urogenital problems                                |

| Transfer from MHT to tibolone                         |
|------------------------------------------------------|
| • Mastalgia or breast tension                        |
| • Increased breast density with need to repeat mammography or when the mammogram is unreadable |
| • Mood swings                                        |
| • Sexual appetite disorders                          |
| • Irregular bleeding without a histopathological finding |

| Women without acute climacteric syndrome             |
|------------------------------------------------------|
| • Lowered sexual appetite                            |
| • Mood swings                                        |
| • Osteopenia                                        |

| Younger women – possible use                          |
|------------------------------------------------------|
| • Premature ovarian failure – with sexual dysfunction and mood swings |
| • Long-term add-back therapy of agonists GnRH        |

GnRH, gonadotropin-releasing hormone; MHT, menopause hormone therapy.
Selective estrogen receptor modulators

The clinically oldest selective estrogen receptor modulator (SERM), tamoxifen, acts in breast tissue as an estrogen antagonist and therefore it is used in treatment and chemoprevention of breast carcinoma while its agonistic effect causes endometrial hyperplasia.³⁹

Bazedoxifene (BZA) is a new SERM that verifiably reduces bone mass loss in postmenopausal women and reduces the risk of vertebral and nonvertebral (in the high-risk group) fractures without stimulating breast tissue or endometrium.⁴⁰ It can be used for treatment or prevention of osteoporosis in postmenopausal women. It does not stimulate the mammary gland or the endometrium. When used at a dose of 20 or 40 mg per day, it protects the endometrium during systematic estrogen treatment (tissue selective estrogen complexes [TSECs]).⁴¹

Nonhormonal therapy

The climacteric syndrome can also be treated nonhormonally. The preparations used may improve symptoms of acute estrogen shortage to a certain extent but their effect on long-term changes caused by estrogen deficiency has never been proved.

Reflexive electro-analgesia, spa treatment, and physical exercise are possible therapeutic elements that can remedy regimen flaws and lifestyles that do not include adequate physical activity.

Antidepressants

The selective serotonin reuptake inhibitors (SSRI), paroxetine⁴² and venlafaxine, may reduce hot flushes. It has been examined in more than 4200 women in total. Venlafaxine (100 mg) produced a significant reduction of number and intensity of hot flushes and episodes of night awakenings after 4 and 12 weeks of use (p < 0.001).⁴³ Some small studies show usefulness of gabapentin⁴⁴ and clonidine.⁴⁵

Phytoestrogens

Phytoestrogens improve symptoms of acute climacteric syndrome.⁴⁶ However, the studies proving their efficiency are considerably nonhomogenous. Phytoestrogens are nonsteroid plant-derived compounds able to produce an estrogenic effect. They are usually divided into three groups:

- isoflavones (daidzein, genistein, biochanin A, formononetin, glycitein)
- lignans (secoisolariciresinol-diglucosid, matairesinol)
- coumestans.

Epidemiologic observations of Asian women whose lifelong diet contains large quantity of phytoestrogens have shown significantly lower occurrence of acute climacteric syndrome and osteoporosis but also of lifestyle diseases including breast carcinoma than in European and North American women populations. There is a clear link between the consumption of soy rich in isoflavones and lower risk of the breast cancer; however, it is strongly dependent on the age when the intake of soya started.⁴⁷,⁴⁸

The main source of phytoestrogens is soya. In our natural environment, most phytoestrogens are found in red clover and alfalfa in bloom and their germinated seeds. The important sources of phytoestrogens are varieties of cohosh, red grapevine, cereals, rice, strawberries, garlic, liquorice, and dates.

CRE

An extract made of root of the Black cohosh (Cimicifuga racemose), CRE, contains 43 triterpene glycosides and more than 20 polyphenols. They are able to inhibit α-amyrase, carboxypeptidase, and collagenase, and have anti-inflammatory and natural antioxidizing effect. An important component is n(omega)-methylserotonin that reduces serotonin reuptake. That could explain its effect on the climacteric syndrome.⁴⁹

The efficacy of CRE in the treatment of the vegetative climacteric syndrome has been proved by a meta-analysis of nine clinical randomized double-blind studies with the reduction of problems by 26% against placebo.⁵⁰

There are no changes in the plasma profile of sex hormones, which confirms the theory of an effect on the central nervous system. Almost zero stimulation of estrogen receptors enables, for example, women with the case history of breast carcinoma to use CRE for the treatment of the climacteric syndrome.⁵¹

Pollen extracts

Pollen extracts have been used as an alternative therapy of the climacteric syndrome. While some widely used bee products contain whole pollen grain, and they are a variable blend of different plants’ pollen, the patented purified cytoplasms of pollen extract P182/GC Fem is extracted from exactly defined monocultures.⁵²

The extract does not have any estrogenic activity. It inhibits reuptake of serotonin in the hypothalamus similarly to SSRI, which influences sleep and thermoregulation. However, unlike SSRI, it does not in any way influence enzymes involved in the metabolism of tamoxifen.

In a prospective, open, multicenter study, 160 mg (twice daily) of pollen extract was able to reduce significantly menopausal symptoms such as vasomotor symptoms, fatigue, irritability, depression, or vaginal dryness.⁵³
Genitourinary syndrome of menopause

Skin atrophy caused by estrogen deficiency including adnexas of vulva and vaginal mucosa is an example of VVA – vulvovaginal atrophy combined with dyspareunia, pruritus, and chronic vaginitis. Estrogen replacement is a dominant form of treatment and the only causal therapy of vaginal atrophy. Estradiol (E2) is administered in a starting dose of 0.5 mg/24 hours for 2–3 weeks in the beginning of the therapy and later in a maintenance dose of 0.5 mg 1–2 times per week. Estradiol (E2) may be administered in the form of vaginal tablets in a dose of 0.01 mg daily for 10–14 days in the beginning, then twice per week.

Long-term administration of higher doses of estrogens could have undesirable trophic effects on the endometrium but at prescribed doses this danger is eliminated – with a total dose of 1.14 mg of estradiol per year, it is possible to treat the symptoms of vaginal atrophy safely and effectively.54 Ospemifene in a daily dose of 60 mg is also approved for VVA treatment in postmenopausal women. It reduces the percentage of parabasal cells in vaginal cytology by 30–40%, increases the number of superficial cells by 5–10%, and lowers the vaginal pH. It reduces dyspareunia and vaginal dryness. It improves sexual functions in postmenopausal women. Ospemifene does not affect hematologic, biochemical, and renal indicators. Its effect on the lipid profile is positive. The most frequent undesirable side effects are hot flushes (7.5% against 2.6 using placebo), vaginal discharge (3.8% against 0.3%), and muscle spasms (3.2% against 0.9). A higher frequency of cardiovascular accidents, proliferative effects on the endometrium, or a negative effect on breast tissue have not been proved.55

Women who are wary of hormone therapy may be administered preparations with hyaluronic acid or prasteron to improve the vaginal trophic condition.56 Some uncontrolled studies exist for usage of fractional CO2 laser or erbium laser.57 Vaginal moisturizers and lubricants are commonly used as symptomatic help for sexual intercourse in elderly age.

The trophic effect of estrogens administered vaginally is irreplaceable in the treatment of vaginal atrophy. It can be used as an individual therapy or in combination in women for whom the overall administration of systemic MHT or tibolone would not be sufficient.

Conclusion

Menopause hormone therapy still remains a dominant therapeutic modality in climacteric medicine. The core medical skill is the ability to choose the optimal MHT preparation for the given patient. Such choice is based on an understanding of various clinical and metabolic effects of MHT depending on the composition, dosage, and the method of application (Box 3). The general trends are individualization, dose minimization, and early start of therapy. When those rules are observed, the benefits of therapy will prevail over its risks.

There are nonhormonal and nonpharmacological alternatives for the treatment of acute climacteric syndrome – while they may have a better safety profile, they are less effective. Pharmacotherapy should be regarded as only one of the pillars of the comprehensive care for aging menopausal woman.

Box 3. Indications of MHT.

- Climacteric syndrome
  - vasomotor problems
  - psychic problems
- Estrogen-deficiency syndrome
  - organic – urogenital atrophy
  - metabolic – osteoporosis
  - primary prevention of the ischemic cardiac disease; with early start only
- Expected effects of long-term administration of estrogens – contrary to the risks of the long-term use
  - Prevention of Alzheimer's disease and Parkinson's disease and strengthening their treatment
  - Prevention of senile macular degeneration and geriatric blindness
  - Prevention of geriatric tooth loss and oral health
  - Prevention of colorectal cancer

MHT, menopause hormone therapy.
Correct attribution: Copyright © 2019 Fait T. https://doi.org/10.7573/dic.212551. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/menopause-hormone-therapy:-latest-developments-and-clinical-practice

Correspondence: Tomas Fait, Department of Obstetrics and Gynecology, Faculty Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. tfait@seznam.cz

Provenance: invited; externally peer reviewed.

Submitted: 12 July 2018; Peer review comments to author: 21 August 2018; Revised manuscript received: 10 December 2018; Accepted: 10 December 2018; Publication date: 2 January 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT. BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

References

1. Archer DF, Baber RJ, Barlow D, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011;14:302–320. http://dx.doi.org/10.3109/13697137.2011.570590
2. Birkhauser MH, Panay N, Archer DF, et al. Updated recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric. 2008;11(2):108–124. http://dx.doi.org/10.1080/13697130801983921
3. Fait T, Fialova A, Pastor Z. The use of estradiol metered-dose transdermal spray in clinical practice. Climacteric. 2018;21(6):1–5. http://dx.doi.org/10.1080/13697137.2018.1504916
4. Lytinen H, Pulkka E, Yliskorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113(1):65–73. http://dx.doi.org/10.1097/AOG.0b013e31818ec6d6
5. Maclellan AH, Broadbent JL, Lester S, Moore V. Oral estrogen and combined estrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;4:CD002978. http://dx.doi.org/10.1002/14651858.CD002978.pub2
6. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. http://dx.doi.org/10.3109/13697137.2015.1129166
7. Attarian H, Hachul H, Guttoso T, Philips B. Treatment of chronic insomnia disorder in menopause: evaluation of literature. Menopause. 2015;22:674–684. http://dx.doi.org/10.1097/GME.0000000000000348
8. Santoro N, Worsley R, Miller KK, et al. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med. 2016;13:305–316. http://dx.doi.org/10.1016/j.jsxm.2015.11.015
9. Wierman ME, Artl W, Basson R, et al. Androgen therapy in women. J Clin Endocrinol Metab. 2014;99:3489–3510. http://dx.doi.org/10.1212/jc.2014.2260
10. Vujovic S, Brincat M, Erel T, et al. EMAS position statement: managing women with premature ovarian failure. Maturitas. 2010;67:91–93. http://dx.doi.org/10.1016/j.maturitas.2010.04.011
11. Utian WH, Woods NF. Impact of hormone therapy on quality of life after menopause. Menopause. 2013;20:1098–1105. http://dx.doi.org/10.1097/GME.0b013e318298debe
12. Emmerson E, Hardman MJ. The role of estrogen deficiency in skin ageing and wound healing. Biogerontology. 2012;13:3–20. http://dx.doi.org/10.1007/s10522-011-9322-y
13. Zetterberg M. Age-related eye disease and gender. Maturitas. 2016;83:19–26. http://dx.doi.org/10.1016/j.maturitas.2015.10.005
14. Nedergaard A, Henriksen K, Karsdal MA, Christiansen C. Menopause, estrogens and frailty. Gynecol Endocrinol. 2013;29:418–423. http://dx.doi.org/10.3109/09513590.2012.754879
15. Hauvais Jarvis F, Manson JE, Stevenson JC, Fonseca VA. MHT and Type 2 Diabetes prevention. Endocrin Rev. 2017;38(3):173–188. http://dx.doi.org/10.1210/er.2016-1146
16. Van Pelt RE, Gavin KM, Kohrt WM. Regulation of body composition and bioenergetics by estrogen. Endocrinol Metab Clin North Am. 2015;44:663–676. http://dx.doi.org/10.1016/j.ecl.2015.05.011
17. Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry. 2015;72:714–726. http://dx.doi.org/10.1001/jamapsychiatry.2015.0111
18. Espeland MA, Shumaker SA, Leng I, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013;173:1429–1436. http://dx.doi.org/10.1001/jamainternalmed.2013.7727
19. Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and Alzheimer disease: a prospective cohort study. Neurology. 2017;88:1062–1068. http://dx.doi.org/10.1212/WNL.0000000000003696
20. Fait T, Vrablik M. Coronary heart disease and hormone replacement therapy – from primary and secondary prevention to the window of opportunity. Neuro Endocrinol Lett. 2012;33(Suppl. 2):17–21.
21. Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in peri-menopausal woman. Eur Heart J. 2007;28:2028–2040. http://dx.doi.org/10.1053/S0140-6736(97)08233-0
22. Hodis HN, Collins P, Mack WJ, Scherbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future perspective. Climacteric. 2012;15:217–228. http://dx.doi.org/10.3109/13697137.2012.656401
23. de Lignières B, Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: individual dose/effect relationship. Maturitas. 1982;4(1):67–72. http://dx.doi.org/10.1016/0378-5122(82)90021-4
24. Arbuckle R, Humphrey L, Abraham L. Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in post-menopausal women to inform the development of new patient-reported measurement tools. Maturitas. 2014;78(3):219–227. http://dx.doi.org/10.1016/j.maturitas.2014.04.019
25. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005;105(5 Pt 1):1063–1073. http://dx.doi.org/10.1097/01.AOG.0000158120.47542.18
26. Baber RJ, Panay N, Fenton A. And the IMS Writing Group: 2016 IMS Recommendation on women's midlife health and menopause hormone therapy. Climacteric. 2016;19:109–150. http://dx.doi.org/10.3109/13697137.2015.1129166
27. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and HRT. http://dx.doi.org/10.7573/dic.212551
28. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005;105(5 Pt 1):1063–1073. http://dx.doi.org/10.1097/01.AOG.0000158120.47542.18
29. Canonico M, Orger E, Plu-Bureasu G, et al. Estrogen and thromboembolism among postmenopausal women. Circulation. 2007;115:840–845. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.642280
30. Writing Group for the Women's Health Initiative Investigators. JAMA. 2002;288(3):321–333. http://dx.doi.org/10.1001/jama.288.3.321
31. Bruce D, Robinson J, McWilliams S, et al. Long-term effects of tibolone on mammographic density. Fertil Steril. 2004;82(5):1343–1347. http://dx.doi.org/10.1016/j.fertnstert.2004.03.063
32. Yenen MC, Dede M,Goktolga U, et al. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy. Climacteric. 2003;6:146–150. http://dx.doi.org/10.1080/13697137.2003.1011732
33. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. Maturitas. 2005;51:21–28. http://dx.doi.org/10.1016/j.maturitas.2005.02.011
34. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697–708. http://dx.doi.org/10.1056/NEJMoa0800743
35. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind randomized, non-inferiority trial. Lancet Oncol. 2009;10(2):135–146. http://dx.doi.org/10.1016/S1470-2045(08)70341-3
36. Schwers J, Eriksson N, Wiquist N, Diczfalusy E. 15α-hydroxylation: a new pathway of estrogen metabolism in the human fetus and newborn. Biochem Biophys Acta. 1965;100:313–316. http://dx.doi.org/10.1016/0005-2760(65)90464-2
37. Visser M, Coellghk Bennink HJT. Clinical application for estetrol. J Steroid Biochem Mol Biol. 2009;114:85–89. http://dx.doi.org/10.1016/j.jsbmb.2008.12.013
38. Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47–58. http://dx.doi.org/10.1542/cmt.2008.11030
39. Lee S, Kim YH, Kim SC, et al. The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer. Obstet Gynecol Sci. 2018;61(5):615–620. http://dx.doi.org/10.5468/ogs.2018.61.5.615
40. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a SERM: effects on the endometrium, ovarium and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009;16:1109–1115. http://dx.doi.org/10.1097/gme.0b013e3181a818db
41. Pinkerton JV, Kamm BS, Mirkin S. Tissue selective estrogen complex combination with bazedoxifene/conjugated estrogens as a model. Climacteric. 2013;16:618–628.
42. Rahimzadeh P, Imani F, Nafissi N, et al. Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors. Cancer Manag Res. 2018;10:4831–4837. http://dx.doi.org/10.2147/CMAR.S173511
43. Joffe H, Guthrie KA, La croix AZ, et al. Low-dose estrogen and the serotonin-norepinephrin reuptake inhibitor venlafaxine for vasomotor symptoms. JAMA Intern Med. 2014;174:1058–1066. http://dx.doi.org/10.1001/jamainternmed.2014.1891
44. Panday KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer. Lancet. 2005;366:818–824. http://dx.doi.org/10.1016/S0140-6736(05)67215-7
45. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155–1172. http://dx.doi.org/10.1097/GME.0000000000000546

Fait T. Menopause hormone therapy: latest developments and clinical practice. Drugs in Context 2019; 8: 212551. DOI: 10.7573/dic.212551
ISSN: 1740-4398
8 of 9
46. Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;12:CD001395. http://dx.doi.org/10.1002/14651858
47. Gold EB, Leung K, Crawford SL, et al. Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms: results from the Study of Women's Health Across the Nation. Menopause. 2013;20(3):305–314. http://dx.doi.org/10.1097/GME.0b013e31826d2f43
48. Fritz H, Seely D, Flower G, et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One. 2013;8(11):e81968. http://dx.doi.org/10.1371/journal.pone.0081968
49. Powell SL, Gödecke T, Nikolic D, et al. In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent. J Agric Food Chem. 2008;56(24):11718–11726. http://dx.doi.org/10.1021/jf803298z
50. Beer AM, Osmers R, Schnitker J, et al. Efficacy of black cohosh (Cimicifuga racemosa) medicines for treatment of menopausal symptoms – comments on major statements of the Cochrane Collaboration report 2012 “black cohosh (Cimicifuga spp.) for menopausal symptoms (review)”. Gynecol Endocrinol. 2013;29(12):1022–1025. http://dx.doi.org/10.3109/09513590.2013.831836
51. Henneicke-von Zepelin HH. 60 years of Cimicifuga racemosa medicinal products: clinical research milestones, current study findings and current development. Wien Med Wochenschr. 2017;167(7–8):147–159.
52. Hellström AC, Muntzing J. The pollen extract Femal – a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause. 2012;19(7):825–829. http://dx.doi.org/10.1097/gme.0b013e31824017bc
53. Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérélys® in the management of women with menopausal symptoms. Gynecol Endocrinol. 2018;34. [In Press].
54. The NAMS 2017 Hormone Therapy Position Statement. Menopause. 2017;24(7):728–753. http://dx.doi.org/10.1097/GME.0000000000000921
55. Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015;18:233–240. http://dx.doi.org/10.3109/13697137.2014.975199
56. Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22:650–663. http://dx.doi.org/10.1097/GME.0000000000000428
57. Rabley A, O’Shea T, Terry R, et al. Laser therapy for genitourinary syndrome of menopause. Curr Urol Rep. 2018;19(10):83. http://dx.doi.org/10.1007/s11934-018-0831-y